No Prescription |
 |
 | ||
|
Norimin Generic Ethinyloestradiol |
|
| ||
No Prescription » Prescription Drugs 12 » Norimin Generic Ethinyloestradiol Norimin is a birth control pill commonly known as a "Combined Oral Contraceptive" that contains both an oestrogen (ethinyloestradiol) and progestogen (norethisterone) hormone.Oral contraceptives belonging to this group produce their birth control (or contraceptive) effect by preventing ovulation (or the release of an egg from the ovary) during each menstrual cycle. Combined Oral Contraceptives also cause changes to the mucus of the cervix and the lining of the womb which contribute to the contraceptive action.If taken according to directions the combined oral contraceptives are very effective in preventing pregnancy. The failure rate of this type of contraceptive is such that for every 1 000 women using the pill for one year two will become pregnant. Buy Norimin Generic Ethinyloestradiol and other Prescription Drugs 12 products online at Medstore. 5347
About Norimin Generic Ethinyloestradiol: Product Type: Prescription Drugs 12 Norimin ( Generic Ethinyloestradiol/Norethisterone ) Norimin (Generic Ethinyloestradiol/Norethisterone) Generic Ethinyloestradiol/Norethisterone 35mcg/500mcg 3 x 28 Tablets Generic Ethinyloestradiol/Norethisterone Norimin
View more Prescription Drugs 12 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
